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ABSTRACT
Introduction: High-risk prescribing in primary care is
common and causes considerable harm. Feedback
interventions to improve care are attractive because
they are relatively cheap to widely implement. There is
good evidence that feedback has small to moderate
effects, but the most recent Cochrane review called for
more high-quality, large trials that explicitly test
different forms of feedback.
Methods and analysis: The study is a three-arm
cluster-randomised trial with general practices being
randomised and outcomes measured at patient level.
262 practices in three Scottish Health Board areas have
been randomised (94% of all possible practices). The
two active arms receive different forms of prescribing
safety data feedback, with rates of high-risk prescribing
compared with a ‘usual care’ arm. Sample size
estimation used baseline data from participating
practices. With 85 practices randomised to each arm,
then there is 93% power to detect a 25% difference in
the percentage of high-risk prescribing (from 6.1% to
4.5%) between the usual care arm and each intervention
arm. The primary outcome is a composite of six high-
risk prescribing measures (antipsychotic prescribing to
people aged ≥75 years; non-steroidal anti-inflammatory
drug (NSAID) prescribing to people aged ≥75 without
gastroprotection; NSAID prescribing to people
prescribed aspirin/clopidogrel without gastroprotection;
NSAID prescribing to people prescribed an ACE
inhibitor/angiotensin receptor blocker and a diuretic;
NSAID prescription to people prescribed an oral
anticoagulant without gastroprotection; aspirin/
clopidogrel prescription to people prescribed an oral
anticoagulant without gastroprotection). The primary
analysis will use multilevel modelling to account for
repeated measurement of outcomes in patients
clustered within practices.
Ethics and dissemination: The study was reviewed
and approved by the NHS Tayside Committee on
Medical Research Ethics B (11/ES/0001). The study will
be disseminated via a final report to the funder with a
publicly available research summary, and peer reviewed
publications.
Trial registration: ClinicalTrials.gov, dossier number
NCT01602705.
BACKGROUND
Used appropriately, prescription drugs signiﬁ-
cantly improve patient outcomes, but
inappropriate use in both hospital and
primary care is a major cause of harm.1–3
Adverse drug events (ADEs) account for
∼6.5% of all hospital admissions,1 and at least
ARTICLE SUMMARY
Article focus
▪ This paper describes a protocol for a cluster-
randomised trial evaluating the impact on high-risk
prescribing of two different designs of feedback
compared to a simple educational message.
Key messages
▪ High-risk prescribing and adverse drug events
are common
▪ Feedback interventions are known to have small
to moderate effects on targeted quality, but few
trials have examined safety data feedback.
Strengths and limitations of this study
▪ The study addresses areas identified as needing
more research in the 2010 Cochrane review of
audit and feedback, including measurement of
baseline performance, theory based development
of interventions, head to head comparison of dif-
ferent feedback designs, and large scale (262
general practices). The intervention is embedded
in real-world data systems and designed to feas-
ible to implement at scale, but a potential limita-
tion is that it may not be intensive enough to
show benefit.
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half of these are preventable.2 The most frequent classes
of drug implicated are antiplatelet drugs including
aspirin, diuretics, non-steroidal anti-inﬂammatory
drugs (NSAIDs), warfarin, opioids, β-blockers and ACE
inhibitors (ACEI)/angiotensin receptor blockers (ARB).2
Deaths are most frequently associated with NSAIDs and
antiplatelet prescribing.1 In addition, there have been a
number of national safety alerts for less commonly pre-
scribed drugs which have been regularly implicated in
preventable deaths. Examples include guidance on
methotrexate prescribing and monitoring,4 and anti-
psychotic use in older people with dementia.5
There are a number of existing measures of poten-
tially inappropriate or high-risk prescribing. Examples
include relevant indicators from the Assessing Care of
Vulnerable Elders (ACOVE) project,6 the Screening
Tool of Older Persons’ Potentially inappropriate
Prescriptions (STOPP) and the Beers Criteria.7 8
However, ACOVE and STOPP rely on manual record
review and are therefore not easily applied on a large
scale. Although the Beers Criteria can be relatively easily
measured using routine healthcare data, the drugs listed
do not include those most commonly implicated in
serious harm which makes them less useful in safety
improvement.
We have recently deﬁned a new set of indicators of
high-risk prescribing which can be measured using
routine electronic data,9 and have applied a subset of 15
indicators to routine clinical data extracted from 315
(∼30%) Scottish practices, focusing on drugs most likely
to cause harm.1 2 10 The indicators related to NSAIDs
(prescription in people at high risk of GI bleeding
without gastroprotection, in renal impairment,
co-prescription with ACEI/ARB and diuretics), warfarin
(co-prescription of NSAIDs, antiplatelets, high-risk anti-
biotics and oral azole antifungals), methotrexate
(co-prescription of both 10 and 2.5 mg tablets), antispsy-
chotic prescription in older people with dementia and
prescription of drugs to avoid in heart failure (NSAIDs,
tricyclics, glitazones, verapamil and others). In total,
19 308 (13.9% of patients included in one or more
denominators) had received one or more high-risk pre-
scriptions in the previous year. On the basis of these
data, 60 000 patients in Scotland will be exposed to this
high-risk prescribing annually. After adjustment for
patient casemix in terms of age, sex, deprivation and
number of prescribed medicines, there remained con-
siderable variation between practices in rates of high-risk
prescribing, with patients in some practices being twice
as likely to receive a high-risk prescription than average.
High-risk prescribing is therefore both common and
highly variable between practices.10 Although not all
these prescriptions will be inappropriate, the high preva-
lence and high variation indicate that this is very likely
to be improvable.
Health systems internationally have sought to improve
the quality and safety of prescribing while controlling or
ideally reducing costs, although primary care ‘prescribing
improvement’ activity in the UK has predominately
focused on costs. This partly reﬂects that existing
National Health Service (NHS) data systems can easily
measure the total cost and volume of different drugs
used by general practices, but cannot usually assess pre-
scribing quality and safety because this usually needs
patient-level data. However, the NHS in all four UK coun-
tries are developing centrally held patient-level prescrib-
ing datasets that make new kinds of measures possible.
NHS Scotland has implemented an ePrescribing pro-
gramme which has created a Scotland-wide, patient-level
prescribing data warehouse (the new Prescribing
Information System or newPIS). newPIS is held by the
Information Services Division (ISD), and ∼95% of pre-
scribed items since April 2009 have a unique patient iden-
tiﬁer attached, with data available within 8–12 weeks of a
drug being prescribed (the delay being due to the phar-
macy payment process). Available data include patient
demography, drug prescribed, prescribing date, dispens-
ing date, and practice code and practice characteristics.
This study takes advantage of this unique opportunity to
develop and rigorously test new forms of prescribing
safety feedback for use across an entire healthcare system.
Providing feedback of performance is an attractive
approach to improving prescribing safety since it is easily
scalable and relatively inexpensive to deploy widely,
allowing more expensive interventions to be deployed
more selectively. There is evidence that feedback can be
effective. At the time of designing the study, the most
recent Cochrane review (2006) identiﬁed 118 rando-
mised trials of clinical audit and feedback, although
many were small and 80% were methodologically ﬂawed
or weak.11 The median effect size was of a 5% absolute
improvement in binary indicators of guideline compli-
ance, but with a very wide range in individual studies
from a 16% absolute worsening to a 70% absolute
improvement. Only a very small number of studies exam-
ined feedback of safety data, mostly relating to benzodi-
azepine prescribing in the elderly.11 The authors
recommended that more high-quality trials were
needed. Such trials require baseline measurement,
clearly deﬁned primary outcomes, and have to be large
enough to reliably detect the small to moderate effect
sizes that are likely. Key gaps in the existing evidence lit-
erature relate to feedback design, with a need for more
theory-informed design12 and ‘for head to head compar-
isons of different ways of doing audit and feedback’.11
The Effective Feedback to Improve Primary Care
Prescribing Safety (EFIPPS) study therefore developed
two theory-informed formats for prescribing safety feed-
back, with the aim of testing their effectiveness com-
pared to simple ‘factual’ educational material in a large,
cluster randomised trial.
We hypothesise that feedback and feedback plus a
health psychology informed intervention delivered to
practices will reduce high-risk prescribing to patients
compared to a simple educational intervention alone.
The speciﬁc objectives are:
2 Guthrie B, Treweek S, Petrie D, et al. BMJ Open 2012;2:e002359. doi:10.1136/bmjopen-2012-002359
Protocol for the EFIPPS study
copyright.
 o
n
 20 August 2019 at University of Aberdeen. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2012-002359 on 13 December 2012. Downloaded from 
1. To test the effectiveness of the two EFIPPS feedback
arms in reducing the speciﬁed primary outcome of a
composite measure of high-risk antipsychotic, non-
steroidal anti-inﬂammatory drug and antiplatelet
drug prescribing;
2. To test the effectiveness of the two EFIPPS feedback
arms in reducing the speciﬁed secondary outcomes
of the six individual measures constituting the
composite;
3. To assess the cost effectiveness of the intervention.
METHODS AND ANALYSIS
Trial design
The outcomes were chosen and the intervention compo-
nents designed in an initial development phase. The
trial is a highly pragmatic, three arm, cluster randomised
controlled trial with the practice as the unit of random-
isation, and outcomes measured at the individual
patient level (ﬁgure 1). A cluster randomised design was
chosen because the feedback intervention being tested
is necessarily targeted at practices or professionals (in
this case practices, as the data are not available at the
individual professional level).
Participants and settings
The trial will be conducted in all eligible general
medical practices in three Scottish Health Boards which
provide healthcare for approximately 1.8 million people
in both urban and rural settings, and across the range of
socioeconomic deprivation. Primary medical care in
these three Health Boards is provided by 279 general
medical practices, and all Boards already use a variety of
means to seek to inﬂuence General Practice prescribing,
including the use of formularies, guidelines, newsletters,
the use of primary care pharmacists to provide prescrib-
ing advice and support for implementation and the
ﬁnancial incentives for prescribing improvement in the
Quality and Outcomes Framework of the GP contract. In
all three Boards, virtually all community prescribing is
done by General Practices and by General Practitioners
in particular (nurses, health visitors and pharmacists are
increasingly prescribing some medicines under deﬁned
protocols, but this is only for a relatively small group of
drugs and currently represents only a small proportion
of total prescribing). The intervention therefore targets
existing teams of professionals working in General
Practices in the three Health Boards.
Inclusion and exclusion criteria
Practice inclusion criteria
▸ General medical practices in the three participating
health boards
Practice exclusion criteria
▸ Practices with registered listsizes <250 patients (all of
these are unusual practices in various ways, for
example serving the homeless or people with challen-
ging behaviour)
▸ Practices with <93% of scripts in the newPIS data
warehouse having a unique patient identiﬁer (the
Community Health Index (CHI) number)
▸ Practices which were formed after 1 January 2011
(since the ﬁrst round of feedback in 2012 includes
historical trend data)
▸ Practices which cease to exist during the trial
▸ Practices which merge during the trial, where the
merging practices were originally in different arms of
the trial
Recruitment of practices
The interventions being implemented in each of the
three arms are variants of existing ‘usual care’, in that
practices are already routinely sent educational material
relating to prescribing safety and feedback about their
prescribing of various kinds (usually comparative cost or
formulary compliance data). With the consent of the
NHS Research Ethics Committee that reviewed the appli-
cation, practices will not be formally recruited or con-
sented to take part. The trial is therefore a highly
pragmatic one, in that all eligible practices will be rando-
mised and followed up.
Figure 1 Effective Feedback to
Improve Primary Care Prescribing
Safety trial design.
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Recruitment of patients
The intervention is targeted at practices, and it remains
at each practice’s discretion whether and when to search
for patients with the speciﬁed high-risk prescribing, to
review their records or the patients themselves, and to
change prescribing (or not). With the consent of the
NHS Research Ethics Committee that reviewed the appli-
cation, there is therefore no recruitment of patients by
the research team.
Intervention components
The intervention was designed to be feasible in real-life
practice, in terms of the time spent on its overall design,
its implementation in existing IT systems at NHS
Scotland Information Services Division, and the fre-
quency and intensity of feedback. For example, feedback
delivery was chosen to be by email because this is deﬁn-
itely achievable routinely, whereas resources for face to
face facilitation by a primary care pharmacist vary by
area, and there are multiple competing demands on
pharmacist resource. All components will be delivered at
practice (cluster) level only, and table 1 shows the
timing of the interventions to be delivered.
1. Educational intervention for all three arms. All educa-
tional material was created by the research team in con-
junction with the study advisory group and where
necessary topic-speciﬁc experts. A short written educa-
tional intervention will be delivered to all practices by
email in the month before the ﬁrst feedback round.
This consists of two pages of text which emphasises that
high-risk prescribing is common and that good practice
is to regularly identify and review patients with it, which
lists the indicators and brieﬂy summarises the risk that
targeted prescribing poses and advice on what to do,
and which directs readers to a website with additional
more detailed educational material.
2. Support for searching for patients in each practice’s own
electronic record for all three arms. The website additionally
has a set of downloadable searches for the two general
practice electronic records in use in Scotland.
3. Feedback of performance on the targeted indicators.
Practices in the two treatment arms (2 and 3) will be
emailed quarterly written feedback of their rate of high-
risk prescribing on ﬁve occasions. Feedback was
designed by the research team working with the study
advisory group which included clinical and managerial
representatives from the three participating Health
Boards and input from the technical team at NHS
Scotland Information Services Division who were respon-
sible for implementation. The feedback consists of a
cover sheet which lists the indicators, a set of six
summary-run charts with a benchmark on one page,
and a more detailed one page summary for each indica-
tor consisting of the same run chart, with additional text
explanation. The run chart shows the practice percent-
age of patients receiving a high-risk prescribing, bench-
marked13 against the lowest quartile for all Scottish
practices in the year before feedback started. Two kinds
of text are included for each indicator. The ﬁrst is the
same for all practices, and explains why the indicator is
important and makes recommendations about what
practices should do (eg, to avoid particular combina-
tions of drugs or review patients with particular prescrib-
ing) in order to make the feedback more
‘actionable’.14 15 The second varies by practice and by
time, since it describes what the run chart is showing, in
terms of how the practice compares to the benchmark
and whether the practice only has a small number of
patients eligible for the indicator.
Feedback is sent quarterly to practices as an attach-
ment to a personalised email signed by a Health Board
primary care clinical manager from the practice’s Board
Table 1 Timeline of interventions to practices in each arm of the trial
Trial arm
Date
Arm 1
Educational intervention only
(control)
Arm 2
Educational intervention
plus quarterly feedback
Arm 3
Educational intervention+quarterly
feedback plus health psychology
informed intervention
June
2012
Sent 2 page educational material
Access via web to more detailed
educational material and patient
searches throughout
Sent 2 page educational material
Access via web to more detailed
educational material and patient
searches throughout
Sent 2 page educational material
Access via web to more detailed
educational material and patient
searches throughout
July 2012 – Feedback 1 Feedback 1 plus action planning
intervention
October
2012
– Feedback 2 Feedback 2 plus perceived
behavioural control intervention
January
2013
– Feedback 3 Feedback 3 plus attitude intervention
April
2013
– Feedback 4 Feedback 4 plus social norms
intervention
July 2013 – Feedback 5 Feedback 5 plus action planning
intervention
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and the Director of the NHS Scotland National
Medicines Utilisation Unit. Each practice will receive ﬁve
rounds of feedback during the trial.
4. Health psychology informed intervention. Practices in
arm 3 will additionally receive a health psychology
informed intervention embedded in the feedback
emailed quarterly on ﬁve occasions. This was designed
by the research team drawing on social cognition
models including both the Theory of Planned
Behaviour (TPB), a motivational model that focuses on
behavioural intention16 and the Health Action Process
Approach (HAPA)17 that has a similar motivational
phase to TPB but also has a volitional phase that focuses
on action-controlled strategies. Four focus groups were
carried out with general practitioners, primary care
pharmacists and prescribing advisers to elicit a broad
range of attitudes, subjective norms and perceived
behavioural control beliefs (barriers) to reviewing
patients with high-risk prescribing and changing their
medication.
Using the information obtained in the focus groups a
two-stage email Delphi study was then delivered to GPs
to prioritise attitudes, norms and barriers to reviewing
patients prescribing in order of those, viewed by GPs, to
be the most important or inﬂuential. The psychology
constructs within each of the social cognition models
were mapped to behaviour change techniques18 and
then, using the results from the email Delphi study, four
one-page interventions were designed targeting each of
the four psychology constructs. Participating practices in
arm 3 receive interventions targeting (in order of
receipt): action planning (HAPA), attitudes (TPB), sub-
jective norms (TPB), perceived behavioural control
(TPB) and a repeat of the action planning intervention
in the ﬁfth round of feedback. The intervention appears
as page 2 in the feedback document.
Outcome measures
The outcome measures were chosen by the EFIPPS
steering group which included representatives from
each of the three Health Boards participating, NHS
Scotland Information Services Division and National
Medicines Utilisation Unit and the research team.
Measures were drawn from those which had been the
subject of a recent formal consensus process to validate
them,9 19 and were selected for their perceived import-
ance to the participating Health Boards and their feasi-
bility to implement in the newPIS data warehouse.
Primary outcome measure
The primary outcome is a composite of the six individ-
ual secondary outcome indicators. At patient level, it is
deﬁned as whether or not a patient who is particularly at
risk of an adverse event from the speciﬁed prescribing
(due to age or co-prescribing) is prescribed one or
more high-risk prescriptions in each quarter. At practice-
level, it is deﬁned as the proportion of patients particu-
larly at risk of an adverse event from the speciﬁed
prescribing, who receives one or more high-risk prescrip-
tions. A composite is reasonable as a coherent measure
of ‘high-risk prescribing’ because each of the underlying
indicators is based on evidence of harm and has been
judged valid in one or more formal consensus
studies.9 19
Secondary outcome measures
The six individual high-risk prescribing measures will be
measured quarterly
1. Oral antipsychotic prescription to a patient aged
75 years and over (as a proxy of oral antipsychotic
prescribing to older people with dementia).5 20 21
2. Oral non-steroidal anti-inﬂammatory drug (NSAID)
prescription to a patient aged 65 years and over who
is currently prescribed a diuretic and an ACE inhibi-
tor or Angiotensin Receptor Blocker (the ‘triple
whammy’).22 23
3. Oral NSAID prescription to a patient aged 75 years
and over who is not currently prescribed a gastropro-
tective drug.24–26
4. Oral NSAID prescription to a patient aged 65 years
and over who is currently prescribed either aspirin or
clopidogrel, but is not currently prescribed a gastro-
protective drug.24 27 28
5. Oral NSAID prescription to a patient currently pre-
scribed an oral anticoagulant but who is not currently
prescribed a gastroprotective drug.24 27 28
6. Aspirin or clopidogrel prescription to a patient cur-
rently prescribed an oral anticoagulant but who is not
currently prescribed a gastroprotective drug.24 27 28
Cost measurement
Data on the resources used to develop the interventions
in each of the three arms will be recorded along with
the resources needed in responding to queries from GP
practices in each arm. In addition the resources used
within GP practices as a result of the intervention will be
estimated based on a sample of GP practices.
Outcome measurement
Primary and secondary outcomes will be measured using
routinely available data from the newPIS data warehouse
held by ISD Scotland.
Sample size
The power calculations were based on a cluster rando-
mised trial and were calculated using the n4prop func-
tion in the CRTSize library in R.29 30 In the period prior
to the study an average of 700 patients per practice were
in one of the composite risk groups. Of these 6.1% had
a high-risk prescription in the previous quarter, and the
intraclass correlation coefﬁcient was 1.26%. There are
two primary comparisons in the study, each of the two
feedback arms compared to standard practice, and each
are to be tested at a signiﬁcance level of 0.025. With 85
practices randomised to each arm, then there is 93%
power to detect a 25% difference in the percentage of
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high-risk prescribing (from 6.1% to 4.5%) between
standard arm and the intervention arm at the end of
the study. A sensitivity analysis of the power to reductions
in the average number of patients in the composite risk
group per practice, reductions in the percentage with a
high-risk prescription and an increase in the intracluster
correlation showed that differences in the range 20–30%
will be detected with a power of at least 80% if as few as
70 practices complete the study (table 2).
The intraclass correlations for the secondary outcome
5 measure (NSAID prescribed to a patient prescribed
oral anticoagulation without gastroprotection) is 14.5%
and there is no power to detect any differences for this
single end point. For the other ﬁve secondary outcomes,
the intraclass correlation range from 1.3% for those
based on all patients aged 75 and over to 4.9% for sec-
ondary outcome 6 (antiplatelet prescribed to a patient
prescribed oral anticoagulation without gastroprotec-
tion). With a sample size of 80 practices per arm, there
is a power of at least 90% to detect differences of 40%,
or 80% power for differences of 35%, on each of the
individual measures.
Randomisation and allocation concealment
The three Health Boards were recruited to be represen-
tative of the types of practices in Scotland. In total, 262
(94.3%) practices in the three participating boards satis-
ﬁed the eligibility criteria and were randomised. There
Table 2 Powers to detect the specified percentage reductions in the percentages of high-risk prescribing associated with a
variety of intra class correlations (ICC), average practice size, anticipated percentages of high-risk prescribing in the control
arm and numbers of practices randomised
Percentage
control (%)
Percentage
intervention (%)
Percentage
reduction
ICC
(%)
Average
practice
size
Number
practices
control
Number
practices
intervention Power
6.1 4.8 21 1.3 700 85 85 0.80
6.1 4.7 22 1.3 700 79 79 0.81
6.1 4.7 22 1.3 700 75 75 0.79
6.1 4.7 23 1.3 700 70 70 0.80
6.1 4.5 25 1.3 700 85 85 0.93
6.1 4.5 25 1.3 700 79 79 0.91
6.1 4.5 26 1.3 700 75 75 0.92
6.1 4.5 26 1.3 700 70 70 0.90
6.1 4.5 25 1.3 700 85 85 0.93
6.1 4.4 27 1.3 700 79 79 0.95
6.1 4.4 27 1.3 700 75 75 0.94
6.1 4.4 28 1.3 700 70 70 0.94
6.1 4.7 23 1.9 700 70 70 0.80
6.1 4.7 23 1.9 700 75 75 0.83
6.1 4.8 21 1.9 700 85 85 0.80
6.1 4.5 26 1.9 700 70 70 0.90
6.1 4.5 26 1.9 700 75 75 0.92
6.1 4.4 28 1.9 700 70 70 0.94
6.1 4.4 27 1.9 700 75 75 0.94
6.1 4.5 25 1.9 700 85 85 0.93
6.1 4.7 23 1.3 600 70 70 0.79
6.1 4.7 23 1.3 600 75 75 0.82
6.1 4.7 22 1.3 600 80 80 0.81
6.1 4.5 25 1.3 600 75 75 0.89
6.1 4.5 25 1.3 600 80 80 0.91
6.1 4.6 24 1.3 600 85 85 0.90
6.1 4.4 27 1.3 600 80 80 0.95
6.1 4.4 27 1.3 600 85 85 0.96
4.5 3.4 26 1.3 700 70 70 0.78
4.5 3.4 26 1.3 700 75 75 0.81
4.5 3.4 26 1.3 700 80 80 0.84
4.5 3.4 25 1.3 700 85 85 0.83
4.5 3.2 30 1.3 700 70 70 0.90
4.5 3.2 29 1.3 700 75 75 0.90
4.5 3.3 27 1.3 700 80 80 0.90
4.5 3.3 27 1.3 700 85 85 0.89
4.5 2.9 36 1.3 700 70 70 0.98
4.5 3.2 30 1.3 700 85 85 0.95
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were two stratiﬁcation factors, Health Board and base-
line high-risk prescribing, in tertiles, giving nine strata.
Stratifying by the Health Board was necessary in case a
board-implemented improvement activity designed to
inﬂuence high-risk prescribing, while stratifying by high-
risk prescribing was to achieve balance over the three
treatment arms. No further restriction was placed on the
randomisation other that ensuring that there were
approximately equal numbers in the three treatment
groups in each strata—exact equality was not possible as
the number of practices in each strata was not a multiple
of 3. Rather than randomising fewer practices all eligible
practices were included (table 3).
As all practices were included in the study at one time
there was no need to balance the allocation sequence.
Randomisation to the treatment group was carried out
by the statistical team and the Tayside Clinical Trials
Unit independently allocated each treatment group to
one of the three arms (control arm 1, feedback arm 2,
feedback+psychology informed intervention arm 3).
Practices cannot be blinded to their treatment alloca-
tion, but the statistical team was blinded to this alloca-
tion and will analyse the data blind.
Statistical methods
The main analysis will be through the use of a multilevel
logistic regression model to take into account both
patient-level characteristics and GP practice-level vari-
ables. We will test the effect of both experimental arms
separately against the control arm (at the 2.5% signiﬁ-
cance level) to control for an overall 5% signiﬁcance
level.
The ﬁrst analysis is the comparison of the percentages
of patients in the composite risk groups who have a
high-risk prescription in the quarter following the end
of the study. There are two primary contrasts arm 2 com-
pared to arms 1 and 3 compared to 1. The analysis will
be based on a two-stage hierarchical logistic regression
model, where the cluster is the GP practice, adjusting
for the strata, health board and high-risk prescribing at
baseline. This will be carried out using the lme4
package in R (http://lme4.r-forge.r-project.org/). This
represents the analysis that the study power is based
upon.
The second analysis will take into account the
repeated observations over time and will be based on
individual data from six quarters pre-randomisation and
four quarters postrandomisation. Again a hierarchical
logistic regression model will be used with patients clus-
tered within practices. The primary variables in the
regression model are strata, treatment group and time.
Time will be included as an ordinal factor effect with
the linear trend being the most important term.
Adjustment will be made for individual-level and
practice-level variables in the quarter before randomisa-
tion. It is anticipated that an autoregressive covariance
matrix will be used for the temporal effects though a
general, unconstrained matrix will be investigated. The
choice of appropriate covariance matrix will be based
on penalised log likelihood methods such as AIC. In this
analysis the prime aim is to investigate if the temporal
trends in high-risk prescribing in the two feedback arms
(arms 2 and 3) are different from the trend in the stand-
ard arm (arm 1). This is an interaction test between
treatment group and time in the model. By using
repeated observations from the practices then an
increased precision in the estimated effects is
anticipated.
The primary analysis is based on the composite
measure and the individual measures will be part of the
secondary analysis. The main explanatory variables at
the patient level will be gender, age, socioeconomic
status measured using postcode assigned Scottish Index
of Multiple Deprivation score,31 and comorbidity mea-
sured using hospital admission data. We will also have
information on the main class of prescribing and length
of time on prescription and these may be used if the
quality of the data is sufﬁciently high. At the practice
level we anticipate having data on practice size, accredit-
ation for postgraduate training and previous levels of
high-risk prescribing. The proportion of patients with
high-risk prescribing patterns will be used as an explana-
tory variable in the analysis, through the stratiﬁcation in
the randomisation.
We propose to carry out an interim analysis midway
through the intervention. This analysis, as well as the
ﬁnal analysis, will be blinded to the treatment allocation.
The interim analysis will serve to check the initial assump-
tions made in the power calculation and to validate the
data extraction from the ISD prescribing database.
Furthermore, as the duration of prescribing will be
available we propose to analyse the length of time that
high-risk prescribing has occurred and investigate if this
is shorter in the two feedback arms compared to the
standard control arm. This analysis will be carried out
using a cox proportional hazards model with a random
effect (frailty term) associated with practice.
Table 3 Number of practices randomised to each strata
NHS
health
board
Tertile of rate
of high-risk
prescribing Group A* Group B* Group C*
HB1 4 4 4
HB2 1 (lowest rate) 6 6 6
HB3 19 19 19
HB1 3 4 4
HB2 2 11 11 10
HB3 15 15 15
HB1 9 10 10
HB2 3 (highest
rate)
14 13 14
HB3 6 6 5
*The research team are blind to which arm is control, treatments
1 or 2 (an independent statistician allocated treatment groups to
arms). HB, NHS health board.
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The analysis of the end-of-study data and the time
trend data will be based upon an intention-to-treat ana-
lysis. Drop-out of practices is not expected and use of
imputation methods is not foreseen. Some practices may
merge and others may close or split. The numbers likely
to be involved are small and no special treatment is
required.
Cost-effectiveness methods
The cost-effectiveness analysis will investigate the cost
per reduction in the number of person years over which
individuals are exposed to high-risk prescribing in the
two feedback arms (arms 2 and 3) compared to stand-
ard practice (arm 1). The reduction in the number of
person years over which individuals are exposed to high-
risk prescribing will be based on the composite measure
of high-risk prescribing taking into account quarterly
variations in the estimated intervention effect, after con-
trolling for baseline levels, until one-quarter after the
end of the study. The costs considered in each arm of
the intervention will include both the ﬁxed costs asso-
ciated with developing indicators, feedback templates
and also include those variable costs associated with
responding to queries from GP practices and the actual
GP practice resources involved in changing high-risk
prescribing in terms of GPs’ time taken to; read materi-
als, undertake searches for high-risk patients, review
patients and change prescribing, if needed. The beneﬁts
and costs will be modelled around the potential future
implementation of such an intervention Scotland-wide
given that the ﬁxed costs are unlikely to change;
however, the impact on the cost-effectiveness to changes
in the scale of the intervention will also be analysed.
Uncertainty in terms of costs as well as outcomes will be
explored via a multivariate sensitivity analysis.
ETHICS AND DISSEMINATION
The feedback intervention seeks to prompt a review of
potentially high-risk prescribing to ensure that it is
appropriate, but prescribing decisions and patient care
remains entirely the responsibility of the practice that a
patient is registered with, with any changes in prescrib-
ing being done in the context of normal clinical care.
The Tayside Committee for Medical Ethics B committee
reviewed the study and gave a favourable ethical
opinion. Dissemination will include a ﬁnal report to the
funder with a lay summary for publication, peer-
reviewed journal articles and NHS-targeted summaries
and implementation support material.
CONCLUSION
High-risk prescribing in primary care is common and
varies considerably between practices, and improving
the safety of primary care prescribing is important.10
There is some evidence that relatively intensive interven-
tion involving pharmacist-led review is effective,32 but
such interventions are expensive and may therefore be
difﬁcult to scale. Feedback interventions are much less
resource intensive, and therefore potentially more scal-
able and feasible to use in everyday practice, but most
reported trials have uncertain or high risk of bias,33 and
there is little evidence for their use in improving safety
outcomes.33 The 2012 Cochrane review update authors
echoed the 2006 review11 in recommending that more
high-quality trials were needed, with such trials ideally
having baseline measurement, clearly deﬁned primary
outcomes and being large enough to reliably detect the
small-to-moderate effect sizes that are likely. They specif-
ically state that: “To build upon the current evidence
base, the ﬁeld would beneﬁt from more attention to
four areas: improved reporting and methods; explicit
use of theory, empirical evidence, and logic to develop
hypotheses and to design the intervention and compari-
son arms; a focus on professional practices for which
there is compelling evidence of patient beneﬁts with
clearly deﬁned primary outcomes; and more
head-to-head trials (e.g. comparing different ways of pro-
viding feedback).”33
Although designed before the most recent Cochrane
review,33 the EFIPPS trial fulﬁls the design requirements
cited above (careful design of feedback, clearly deﬁned
primary outcome baseline measurement, large scale);
drew on existing evidence, theory and NHS profes-
sionals’ expertise in designing the feedback to be used;
focused on high-risk prescribing where there is good evi-
dence of the magnitude of harm caused; and includes a
head-to-head comparison of two different forms of feed-
back with different resource implications. It will there-
fore signiﬁcantly add to the existing literature.
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